Physician profile
Sameh S Shenouda
NPI 1487936902
$3,046.30
in general payments reported to CMS, 2019-2025
15 companies · $354 in 2025
The $354 reported for 2025 was more than what 79% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $467 · 2021: $367 · 2022: $485 · 2023: $495 · 2024: $443 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $868.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $509.00 | 2019-2025 | Farxiga, Breztri, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.28 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $354.17 | 2019-2024 | Mounjaro, Zepbound |
| Ironwood Pharmaceuticals, INC | $213.79 | 2020-2024 | Linzess |
| Sanofi-Aventis U.S. LLC | $170.61 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.02 | 2023-2025 | |
| Amgen INC. | $90.25 | 2023-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $87.91 | 2023-2024 | |
| Astellas Pharma US INC | $68.34 | 2021-2023 | Veozah |
| Dexcom, INC. | $64.76 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $38.83 | 2024 | |
| Exact Sciences Corporation | $27.31 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $22.45 | 2020 | |
| Xeris Pharmaceuticals, INC. | $17.30 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameh Shenouda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.